DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bolze, S.
Right arrow Articles by Hulot, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bolze, S.
Right arrow Articles by Hulot, T.

Vol. 30, Issue 4, 404-413, April 2002

Development of an in Vitro Screening Model for the Biosynthesis of Acyl Glucuronide Metabolites and the Assessment of Their Reactivity toward Human Serum Albumin

Sebastien Bolze, Norbert Bromet, Croisine Gay-Feutry, Frederic Massiere, Roselyne Boulieu, and Thierry Hulot

Department of Pharmacokinetics and Metabolism, Lipha S.A., Centre de Recherche Lyon-Lacassagne, Lyon, France (S.B., T.H.); Biotec Centre, Orleans, France (N.B.); Biopredic International, Rennes, France (C.G.F., F.M.); and Département de Pharmacie Clinique, de Pharmacocinétique et Évaluation des Médicaments, Faculté de Pharmacie, Université Lyon, France (R.B.)

An in vitro screening model was developed to determine the reactivity of acyl glucuronide metabolites from carboxylic drugs. This assay is composed of two phases. The first is a phase of biosynthesis of acyl glucuronides by human liver microsomes (HLM). The second, during which acyl glucuronides are incubated with human serum albumin (HSA), consists of assessing the reactivity of acyl glucuronides toward HSA. Both phases are performed successively in the same experiment. This model was validated using eight carboxylic drugs that were well known for their reactivity, their extent of covalent binding, and their immunological potential. These products were representative of the scale of reactivity. Each compound was incubated with HLM at 400 µM and metabolized into acyl glucuronide to different extents, ranging from 5.6% (tolmetin) to 89.4% (diclofenac). The first-order aglycone appearance rate constant and the extent of covalent binding to proteins were assayed during the incubation of acyl glucuronides formed with HSA for 24 h. Extensive isomerization phenomenon was observed for each acyl glucuronide between the two phases. An excellent correlation was observed (r2, 0.94) between the extent of drug covalent binding to albumin and the aglycone appearance constant weighted by the percentage of isomerization. This correlation represents an in vitro reactivity scale, which will be helpful in drug discovery support programs to predict the covalent binding potential of new chemical entities. This screening model will also allow the comparison of acyl glucuronide reactivity for related structure compounds.

Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Toxicol SciHome page
J. S. MacDonald and R. T. Robertson
Toxicity Testing in the 21st Century: A View from the Pharmaceutical Industry
Toxicol. Sci., July 1, 2009; 110(1): 40 - 46.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. P. Williams, D. J. Antoine, P. J. Butler, R. Jones, L. Randle, A. Payne, M. Howard, I. Gardner, J. Blagg, and B. K. Park
The Metabolism and Toxicity of Furosemide in the Wistar Rat and CD-1 Mouse: a Chemical and Biochemical Definition of the Toxicophore
J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1208 - 1220.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
Q. Chen, G. A. Doss, E. C. Tung, W. Liu, Y. S. Tang, M. P. Braun, V. Didolkar, J. R. Strauss, R. W. Wang, R. A. Stearns, et al.
EVIDENCE FOR THE BIOACTIVATION OF ZOMEPIRAC AND TOLMETIN BY AN OXIDATIVE PATHWAY: IDENTIFICATION OF GLUTATHIONE ADDUCTS IN VITRO IN HUMAN LIVER MICROSOMES AND IN VIVO IN RATS
Drug Metab. Dispos., January 1, 2006; 34(1): 145 - 151.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. P. O'Donnell, D. K. Dalvie, A. S. Kalgutkar, and R. S. Obach
MECHANISM-BASED INACTIVATION OF HUMAN RECOMBINANT P450 2C9 BY THE NONSTEROIDAL ANTI-INFLAMMATORY DRUG SUPROFEN
Drug Metab. Dispos., November 1, 2003; 31(11): 1369 - 1377.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
E. J. Perkins, J. W. Cramer, N. A. Farid, M. G. Gadberry, D. A. Jackson, E. L. Mattiuz, D. D. O'Bannon, H. J. Weiss, W. J. Wheeler, P. G. Wood, et al.
PRECLINICAL CHARACTERIZATION OF 2-[3-[3-[(5-ETHYL-4'-FLUORO-2-HYDROXY[1,1'-BIPHENYL]-4-YL)OXY]PROPOXY]-2-PROPYLPHENOXY]BENZOIC ACID METABOLISM: IN VITRO SPECIES COMPARISON AND IN VIVO DISPOSITION IN RATS
Drug Metab. Dispos., November 1, 2003; 31(11): 1382 - 1390.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. Zhang, M. Ogan, R. Gedamke, V. Roongta, R. Dai, M. Zhu, J. K. Rinehart, L. Klunk, and J. Mitroka
PROTEIN COVALENT BINDING OF MAXIPOST THROUGH A CYTOCHROME P450-MEDIATED ORTHO-QUINONE METHIDE INTERMEDIATE IN RATS
Drug Metab. Dispos., July 1, 2003; 31(7): 837 - 845.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.